TOPIC

Innovent Biologics

(信达生物)

Innovent Biologics
信达生物
Established in 2011, Innovent Biologics is a biotechnology company that develops, manufactures and commercialises medicine for oncology, cardiovascular and metabolic diseases, autoimmune diseases and ophthalmology. The Suzhou-headquartered company was listed on the Hong Kong stock exchange on October 31, 2018.
Made in China 2025

China’s pharmaceutical industry transforms into a global innovation powerhouse

The China Pharmaceutical Innovation and Invention Index, a new gauge, highlights top drug makers on the mainland for the first time.

Ascletis trial shows drug candidate ASC47 boosts semaglutide weight loss effect

Wuxi AppTec joins funding rush as appetite grows for China’s biotech

WuxiAppTec raised HK$7.70 billion (US$981 million) in a sale of additional shares to fund its global expansion.

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement